Fedele
Fedele#digitalneurohub
#Biogen
#cascinaerbatici
#dnh
@sinneurologia
#DNH2026
CinqueW NewsANTITRUST
Biogen probed by Italy over MS drug competition
cinquewnews.blogspot.com/2026/05/biog... #Antitrust #Biogen #MultipleSclerosis #MSDrug #PharmaNews #ItalianAntitrust #CompetitionLaw #HealthcareIndustry #Biotech #Natalizumab #Sandoz #DrugMarket #EUCompetition #Pharmaceuticals #MedicalNews
Biogen probed by Italy over MS...
Biogen probed by Italy over MS...
Industry ExaminerWhy did Biogen pay up for Apellis Pharmaceuticals?
Because this may be less about buying a drug and more about buying a nephrology platform.
Our latest argues that kidney disease is starting to look like biotech’s next strategic battleground, and that Biogen’s Apellis deal may be an early signal of where the industry is heading.
Read more: https://biotech.industryexaminer.com/biogen-apellis-kidney-disease-nephrology-biotech/
Zougla.gr#Biogen #νωτιαία_μυϊκή_ατροφία Νωτιαία μυϊκή ατροφία: Νέα δεδομένα για το nusinersen https://www.zougla.gr/ygeia/farmako-nea/notiaia-myiki-atrofia-nea-dedomena-gia-to-nusinersen/?utm_source=dlvr.it&utm_medium=mastodon
Thế Giới Trong Tầm TayTin vui cho bệnh nhân ALS! Biogen đã triển khai Tofersen, liệu pháp nhắm trực tiếp vào gen SOD1 tại Trung Quốc, mở ra hy vọng mới trong điều trị. Mũi tiêm đầu tiên đã được thực hiện tại Bệnh viện Tam Hiệp, đánh dấu bước tiến quan trọng. #ALS #Tofersen #GenTherapy #Biogen #Yhoc https://ift.tt/XcnHhtD
Phương pháp điều trị gen ALS đột phá được triển khai tại Trung Quốc - Thế Giới Trong Tầm Tay
Biogen triển khai Tofersen tại Trung Quốc, loại thuốc nhắm mục tiêu gen đầu tiên dành cho ALS do đột biến SOD1, đánh dấu đột phá trong điều trị.
Tech Cybersecurity NieuwsSage therapeutics verwerpt overnamebod van biogen ter waarde van $469 miljoen https://www.trendingtech.news/trending-news/2025/01/51116/sage-therapeutics-verwerpt-overnamebod-van-biogen-ter-waarde-van-469-miljoen #Sage Therapeutics #Biogen #overnamebod #biotechnologie #aandeelhouders #Trending #News #Nieuws
Fda keurt maandelijkse dosis leqembi goed voor alzheimerpatiënten https://www.trendingtech.news/trending-news/2025/01/51047/fda-keurt-maandelijkse-dosis-leqembi-goed-voor-alzheimerpati-nten #FDA #Alzheimer #Leqembi #Eisai #Biogen #Trending #News #Nieuws
ExTraders GlobalZimmer Biomet ($ZBH) reported EPS of $1.74, matching the forecast of $1.74. Revenue was $1.82B, slightly exceeding the expected $1.8B.
Global Payments ($GPN) achieved EPS of $3.08, just below the forecast of $3.09. Revenue reached $2.6B, surpassing the anticipated $2.38B.
Biogen ($BIIB) posted EPS of $4.08, exceeding the forecast of $3.77. Revenue was $2.47B, slightly above the expected $2.43B.
#Earnings #Q3 #ZimmerBiomet #GlobalPayments #Biogen #Investing #Finance #Stocks #MarketNews
The Japan TimesTwo new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years. https://www.japantimes.co.jp/news/2024/09/21/world/science-health/alzheimers-drugs-controversy/ #worldnews #sciencehealth #dementia #aging #alzheimer039s #eisai #biogen #elililly #drugs #medicine #brain
